Afternoon Headaches: Causes and Management
For afternoon headaches without red flags, start with NSAIDs (ibuprofen 400-800 mg, naproxen sodium 275-550 mg, or aspirin 650-1000 mg) as first-line treatment, and if these fail after adequate trials, escalate to triptans as second-line therapy. 1, 2
Initial Assessment
Before treating, rule out secondary causes by evaluating for:
- Timing patterns: Predictable afternoon onset may suggest tension-type headache (TTH) from accumulated daily stress, muscle tension, or caffeine withdrawal
- Associated symptoms: Sensitivity to light/sound, nausea, or family history points toward migraine
- Red flags requiring immediate evaluation: Thunderclap onset, fever, neck stiffness, focal neurologic deficits, altered consciousness, or new headache after age 50 2, 3
If red flags are absent and neurologic examination is normal, neuroimaging is not indicated 3.
Acute Treatment Algorithm
First-Line: NSAIDs
Use NSAIDs as initial therapy for both migraine and TTH 1, 2:
- Ibuprofen: 400-800 mg every 6 hours (maximum 2.4 g/day)
- Naproxen sodium: 275-550 mg every 2-6 hours (maximum 1.5 g/day)
- Aspirin: 650-1000 mg every 4-6 hours (maximum 4 g/day)
- Combination therapy: Aspirin + acetaminophen + caffeine has proven efficacy 1, 4
Important caveat: Acetaminophen alone is NOT effective for migraine 1. For TTH specifically, acetaminophen 1000 mg or ibuprofen 400 mg can be used 5.
Second-Line: Triptans
If NSAIDs fail after trials in at least 3 consecutive attacks, escalate to triptans 1, 2:
- Oral options: naratriptan, rizatriptan, zolmitriptan, or sumatriptan
- Key principle: Take early when headache is still mild for maximum effectiveness 2
- If one triptan fails, try others—individual response varies 2
- Can combine with fast-acting NSAIDs (naproxen sodium, ibuprofen lysine, or diclofenac potassium) to prevent relapse 2
Critical warning: Limit acute medication use to avoid medication-overuse headache (MOH). Using abortive medications more than twice per week is an indication for preventive therapy 1.
Third-Line: Newer Agents
If all triptans fail or are contraindicated, consider CGRP inhibitors (gepants: ubrogepant, rimegepant) 2, 5.
When to Consider Preventive Therapy
Initiate preventive treatment if 1:
- ≥2 attacks per month producing disability lasting ≥3 days
- Contraindication to or failure of acute treatments
- Using abortive medication more than twice per week
- Quality of life remains impaired despite optimized acute therapy
First-Line Preventive Agents 1, 5:
- Propranolol: 80-240 mg/day
- Timolol: 20-30 mg/day
- Amitriptyline: 30-150 mg/day (also effective for chronic TTH prevention 5)
- Divalproex sodium: 500-1500 mg/day
- Topiramate, lisinopril, angiotensin-receptor blockers, magnesium, or memantine 5
- Newer CGRP monoclonal antibodies or atogepant 5
Start low, titrate slowly—clinical benefit may take 2-3 months to manifest 1. After achieving stability, consider tapering or discontinuing 1.
Adjunctive Management
- For nausea/vomiting: Add prokinetic antiemetics (metoclopramide or domperidone) 2, 4
- Non-pharmacologic options: Physical therapy or aerobic exercise for both migraine and TTH 5
- Patient education: Maintain headache diary tracking frequency, severity, duration, disability, and medication response 1
Medications to Avoid
- Oral ergot alkaloids (poorly effective, potentially toxic)
- Opioids (questionable efficacy, dependency risk, promotes MOH)
- Barbiturates (dependency risk, promotes MOH)
- Gabapentin for episodic migraine prevention 5
Common Pitfalls
- Underutilizing preventive therapy: Many patients continue suffering when they meet criteria for prevention
- Creating medication-overuse headache: Monitor acute medication frequency closely
- Inadequate treatment trials: Give each preventive agent 2-3 months before declaring failure 1
- Missing secondary causes: Always reassess if headache pattern changes or red flags emerge
The evidence strongly supports this stepwise approach, with the most recent 2024 VA/DoD guidelines 5 and 2021 Nature Reviews consensus 2 reinforcing the foundational 2002 Annals of Internal Medicine recommendations 1 that remain the standard of care.